triazoles has been researched along with mdv 3100 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradner, JE; Chan, SC; Dehm, SM; Li, Y; Miao, L; Nyquist, MD; Raj, GV; Selth, LA; Tilley, WD | 1 |
| Bambury, RM; Rathkopf, DE | 1 |
| Apel, IJ; Asangani, IA; Chinnaiyan, AM; Dommeti, VL; Escara-Wilke, J; Feng, FY; Krishnamurthy, PM; Navone, NM; Plymate, SR; Wang, S; Wilder-Romans, K | 1 |
| Abida, W; Armenia, J; Arora, VK; Bernstein, BE; Drier, Y; Freedman, ML; Karthaus, WR; Long, HW; Rockowitz, S; Sawyers, CL; Shah, N; Wang, P; Wongvipat, J; Zheng, D | 1 |
| Aggarwal, R; Chang, E; Fong, L; Friedlander, TW; Kim, W; Lin, AM; Louttit, M; Ryan, CJ; Siegel, AP; Wei, XX; Zhang, L | 1 |
| Alumkal, JJ; Balter, A; Burchard, J; Chiotti, KE; Coleman, DJ; Derrick, DS; Gao, L; Heiser, LM; King, CJ; Schwartzman, J; Sehrawat, A; Sun, D; Tayou, J; Urrutia, J; Xia, Z | 1 |
| Chandler, B; Eisner, J; Feng, FY; Hayes, D; Liu, M; Michmerhuizen, AR; Moubadder, L; Nyati, S; Olsen, E; Pesch, AM; Pierce, LJ; Rae, JM; Ritter, C; Santola, A; Speers, C; Spratt, D; Wahl, D; Ward, ST; Wilder-Romans, K; Zhang, A | 1 |
| Chau, CH; Cordes, LM; Dahut, WL; Eisner, J; Figg, WD; Gulley, JL; Karzai, F; Madan, RA; Moore, WR; Owens, H; Peer, CJ; Schmidt, KT; Steinberg, SM | 1 |
1 review(s) available for triazoles and mdv 3100
| Article | Year |
|---|---|
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Humans; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Receptors, Androgen; Thiohydantoins; Triazoles | 2016 |
2 trial(s) available for triazoles and mdv 3100
| Article | Year |
|---|---|
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Androstenes; Benzamides; Humans; Hydrazines; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Triazoles | 2018 |
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Triazoles | 2020 |
5 other study(ies) available for triazoles and mdv 3100
| Article | Year |
|---|---|
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Topics: Animals; Antineoplastic Agents; Azepines; Benzamides; Cell Line; Cell Line, Tumor; Chromatin; Dimerization; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Male; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Response Elements; Transcriptional Activation; Triazoles | 2015 |
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
Topics: Acetanilides; Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
Topics: Androgen Antagonists; Animals; Azepines; Benzamides; Cell Line, Tumor; Chromatin Immunoprecipitation; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Metabolism, Inborn Errors; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Glucocorticoid; Sequence Analysis; Signal Transduction; Triazoles | 2017 |
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.
Topics: Animals; Azepines; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Biosynthesis; Receptors, Androgen; Transcription Factors; Transcription, Genetic; Triazoles | 2019 |
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Lyases; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Naphthalenes; Nitriles; Phenylthiohydantoin; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |